Working... Menu

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD) (STAIRWAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03038880
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : January 15, 2019
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 12, 2018
  Actual Study Completion Date : March 29, 2018
  Certification/Extension First Submitted : January 11, 2019